Alto Neuroscience Inc (ANRO)

$2.78 -0.10 (-3.47%)
Market Cap 77.97M
Revenue (ttm) 0.00
Net Income (ttm) -61.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.14
Volume 83,000
Avg Vol 282,302
Day's Range N/A - N/A
Shares Out 27.07M
Stochastic %K 64%
Beta 1.65
Analysts Strong Sell
Price Target $11.17

Company Profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule ph...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 200 0412
Address:
650 Castro Street, Suite 450, Mountain View, United States
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Jul. 18 at 7:34 PM
$ATHE $OUST $SLS $PYPD $ANRO Wishing everybody a great weekend... And a reminder:
3 · Reply
XQuise
XQuise Jul. 17 at 5:38 PM
$ANRO 😊
0 · Reply
Moneywheel
Moneywheel Jul. 17 at 3:34 PM
$ANRO above 3,00 USD it could run hard...
0 · Reply
Ccperk
Ccperk Jul. 17 at 3:32 PM
$ANRO is this uptick possibly due to the Blackrock Schedule 13G filing made yesterday?
1 · Reply
DustinTa
DustinTa Jul. 17 at 3:03 PM
$ANRO come on $3.00. Anro I can see you get up there to $3.00.
0 · Reply
kshonstocks
kshonstocks Jul. 17 at 2:59 PM
$ANRO off bottom scans
0 · Reply
Moneywheel
Moneywheel Jul. 17 at 2:47 PM
$ANRO momentum? light volume still but interesting price action. We could move towards 3.00 USD soon. Holding strong.
0 · Reply
Moneywheel
Moneywheel Jul. 17 at 2:12 PM
$ANRO ST is changing a lot. A few years ago there were more users exchanging thoughts and strategies here. It seems as if users were looking to post the right message...you gotta screw things up in order to learn.
0 · Reply
BossTrade
BossTrade Jul. 14 at 6:36 PM
$ANRO Expecting $10-20 pt here
2 · Reply
BossTrade
BossTrade Jul. 14 at 6:36 PM
$ANRO This one is primed to blow up any day
1 · Reply
Latest News on ANRO
Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

Jun 30, 2025, 8:03 AM EDT - 19 days ago

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Jun 26, 2025, 7:33 AM EDT - 23 days ago

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

Jun 3, 2025, 6:03 AM EDT - 6 weeks ago

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

May 29, 2025, 8:03 AM EDT - 7 weeks ago

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

Alto Neuroscience to Participate in Upcoming Investor Conferences

May 28, 2025, 8:03 AM EDT - 7 weeks ago

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 14, 2025, 4:10 PM EDT - 2 months ago

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

Apr 28, 2025, 8:03 AM EDT - 2 months ago

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day

Apr 22, 2025, 8:03 AM EDT - 3 months ago

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

Mar 20, 2025, 4:10 PM EDT - 4 months ago

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation

Mar 1, 2025, 11:00 AM EST - 4 months ago

The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Feb 19, 2025, 8:03 AM EST - 5 months ago

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

Feb 12, 2025, 8:03 AM EST - 5 months ago

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Alto Neuroscience, Inc. For Securities Fraud

Feb 2, 2025, 11:00 AM EST - 5 months ago

The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Alto Neuroscience, Inc. For Securities Fraud

The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Investigation Into Alto Neuroscience, Inc.

Jan 27, 2025, 11:15 AM EST - 6 months ago

The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Investigation Into Alto Neuroscience, Inc.

The Schall Law Firm Invites Investors With Losses To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Jan 24, 2025, 1:15 PM EST - 6 months ago

The Schall Law Firm Invites Investors With Losses To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Jan 22, 2025, 11:45 AM EST - 6 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Alto Neuroscience Inc For Securities Fraud

Jan 3, 2025, 1:30 PM EST - 7 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Alto Neuroscience Inc For Securities Fraud

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Alto Neuroscience Inc For Securities Fraud

Dec 27, 2024, 12:15 PM EST - 7 months ago

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Alto Neuroscience Inc For Securities Fraud

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Alto Neuroscience Inc For Securities Fraud

Dec 21, 2024, 12:15 PM EST - 7 months ago

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Alto Neuroscience Inc For Securities Fraud

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Dec 17, 2024, 1:45 PM EST - 7 months ago

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Dec 15, 2024, 1:45 PM EST - 7 months ago

The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Possible Securities Fraud

Dec 13, 2024, 2:15 PM EST - 7 months ago

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Possible Securities Fraud

The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc.'s Possible Securities Fraud

Dec 11, 2024, 5:15 PM EST - 7 months ago

The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc.'s Possible Securities Fraud

Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology

Dec 11, 2024, 8:03 AM EST - 7 months ago

Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology

The Schall Law Firm Urges Stockholder Contributions To An Inquiry Into Alto Neuroscience, Inc. For Possible Securities Fraud

Dec 9, 2024, 5:30 PM EST - 7 months ago

The Schall Law Firm Urges Stockholder Contributions To An Inquiry Into Alto Neuroscience, Inc. For Possible Securities Fraud

Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Impacted Investors Are Invited To Reach Out To The Schall Law Firm

Dec 8, 2024, 10:30 AM EST - 7 months ago

Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Impacted Investors Are Invited To Reach Out To The Schall Law Firm

The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Fraud

Dec 7, 2024, 12:15 PM EST - 7 months ago

The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Fraud

The Schall Law Firm Encourages Stockholder Contributions To An Inquiry Into Alto Neuroscience, Inc.'s Possible Securities Fraud

Dec 5, 2024, 1:45 PM EST - 8 months ago

The Schall Law Firm Encourages Stockholder Contributions To An Inquiry Into Alto Neuroscience, Inc.'s Possible Securities Fraud

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc.'s Possible Securities Fraud

Dec 3, 2024, 4:45 PM EST - 8 months ago

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc.'s Possible Securities Fraud

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Dec 1, 2024, 1:00 PM EST - 8 months ago

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

The Schall Law Firm Invites Shareholder Contributions To An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Nov 29, 2024, 12:00 PM EST - 8 months ago

The Schall Law Firm Invites Shareholder Contributions To An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Affected Investors Are Encouraged To Reach Out To The Schall Law Firm

Nov 27, 2024, 11:30 AM EST - 8 months ago

Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Affected Investors Are Encouraged To Reach Out To The Schall Law Firm

The Schall Law Firm Invites Stockholder Contributions To An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Nov 26, 2024, 11:30 AM EST - 8 months ago

The Schall Law Firm Invites Stockholder Contributions To An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Investors With Losses Are Urged To Contact The Schall Law Firm

Nov 25, 2024, 12:15 PM EST - 8 months ago

Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Investors With Losses Are Urged To Contact The Schall Law Firm

CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Jul. 18 at 7:34 PM
$ATHE $OUST $SLS $PYPD $ANRO Wishing everybody a great weekend... And a reminder:
3 · Reply
XQuise
XQuise Jul. 17 at 5:38 PM
$ANRO 😊
0 · Reply
Moneywheel
Moneywheel Jul. 17 at 3:34 PM
$ANRO above 3,00 USD it could run hard...
0 · Reply
Ccperk
Ccperk Jul. 17 at 3:32 PM
$ANRO is this uptick possibly due to the Blackrock Schedule 13G filing made yesterday?
1 · Reply
DustinTa
DustinTa Jul. 17 at 3:03 PM
$ANRO come on $3.00. Anro I can see you get up there to $3.00.
0 · Reply
kshonstocks
kshonstocks Jul. 17 at 2:59 PM
$ANRO off bottom scans
0 · Reply
Moneywheel
Moneywheel Jul. 17 at 2:47 PM
$ANRO momentum? light volume still but interesting price action. We could move towards 3.00 USD soon. Holding strong.
0 · Reply
Moneywheel
Moneywheel Jul. 17 at 2:12 PM
$ANRO ST is changing a lot. A few years ago there were more users exchanging thoughts and strategies here. It seems as if users were looking to post the right message...you gotta screw things up in order to learn.
0 · Reply
BossTrade
BossTrade Jul. 14 at 6:36 PM
$ANRO Expecting $10-20 pt here
2 · Reply
BossTrade
BossTrade Jul. 14 at 6:36 PM
$ANRO This one is primed to blow up any day
1 · Reply
BossTrade
BossTrade Jul. 14 at 6:35 PM
$ANRO Guess that wasn’t too great an idea?
0 · Reply
MOOSEN
MOOSEN Jul. 14 at 5:08 PM
$ANRO GOOD-TO-GO? HAVE HAD EYES ON IT.
0 · Reply
Moneywheel
Moneywheel Jul. 14 at 4:11 PM
$ANRO that 2,73$ level key. Gaining ground.
1 · Reply
BossTrade
BossTrade Jul. 9 at 8:14 PM
$ANRO u sound very dramatic. They holding an ace and most here pretend like they’re on life support
1 · Reply
Moneywheel
Moneywheel Jul. 9 at 4:13 PM
$ANRO moment of truth…perhaps one of these days we get a positive surprise on $ANRO performance. Holding strong.
0 · Reply
Moneywheel
Moneywheel Jul. 9 at 3:50 PM
$ANRO 2,70$ is key
1 · Reply
soccerden
soccerden Jul. 9 at 12:40 PM
$ANRO Steady rise up and lack of sellers i like it.we need to break thru resistance at $3.
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jul. 8 at 9:20 PM
Alto Neuroscience ($ANRO) reprices exec options to $2.35 from as high as $14.88. Board aims to retain talent without dilution, but when even your C-suite's options are underwater, maybe it's time to check the lifeboats. Cash burn continues at $16M/quarter. https://www.sec.gov/Archives/edgar/data/1999480/000199948025000061/alto-20250703.htm
2 · Reply
Drugtrade
Drugtrade Jul. 8 at 4:40 PM
$ANRO super undervalued sit tight buy more trim rips
0 · Reply
BulljackHorseman
BulljackHorseman Jul. 8 at 2:59 PM
$ANRO
0 · Reply
BossTrade
BossTrade Jul. 3 at 2:19 PM
$ANRO P3 may be really quick before we do a NDA.
1 · Reply
BossTrade
BossTrade Jul. 3 at 2:18 PM
$ANRO This is not simply a positive readout it is a validation trial for a different parameter. They had 2A and 2B which to me means they’re building a case for fast track and orphan drug, especially given it’s a very underserved health segment.
0 · Reply